Ependymoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ependymoma – Drugs In Development, 2024 report and make more profitable business decisions.
Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment of an ependymoma depends on a number of things, including general health, the size and position of the tumor, and whether it has spread to other parts of the brain or spinal cord.
The Ependymoma drugs in development market research report provide comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ependymoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ependymoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ependymoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ependymoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ependymoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Actuate Therapeutics IncAstraZeneca Plc
Bexion Pharmaceuticals Inc
Bristol-Myers Squibb Co
Candel Therapeutics Inc
Chimerix Inc
Eisai Co Ltd
Eli Lilly and Co
FivePhusion Pty Ltd
Istari Oncology Inc
Lumos Pharma Inc
Mana Therapeutics Inc
Millennium Pharmaceuticals Inc
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
Nationwide Children's Hospital
Novartis AG
OncoTherapy Science Inc
Pediatric Brain Tumor Consortium
Plus Therapeutics Inc
ProLynx LLC
Shanghai Yingli Pharmaceutical Co Ltd
Treovir LLC
Vyro Bio Inc
Wuhan Binhui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ependymoma reports